Home > Articles > Retatrutide mechanism of action: one molecule, three receptors
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
Status: Investigational. Retatrutide is an investigational compound that is being studied in registered phase 3 trials, including TRIUMPH-1 and TRIUMPH-2 [1][2]. A May 2026 industry pipeline summary tracks it as a pipeline candidate [3]. Regulatory status can change, so see our approval status page for the current regulatory record.
Retatrutide is an investigational compound whose phase 3 TRIUMPH trials are registered on ClinicalTrials.gov with Eli Lilly as sponsor [1][2]. Its defining feature is pharmacological. It is a single peptide molecule designed to act at three hormone receptors: the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. The phase 2 papers describe it in exactly those terms. The New England Journal of Medicine paper calls it a "triple-hormone-receptor agonist", and The Lancet paper calls it a "GIP, GLP-1 and glucagon receptor agonist" [4][5].
This page covers the mechanism only. It explains what each receptor does, why a developer would combine all three in one molecule, and what human trials can and cannot reveal about how it works. For trial results and a broader overview, see our retatrutide guide. For how pages on this site are researched and sourced, see About TripleReta.
What "triple agonist" means
An agonist is a molecule that binds a receptor and activates it, mimicking the body's own signalling hormone. Most agonist drugs are built to act at one receptor. Retatrutide is a unimolecular multi-agonist: one chemical entity that interacts with three different receptors, not a mixture of three separate drugs.
Reviews of the obesity drug pipeline describe a progression in this field [6][7][8]:
Single agonists acting at the GLP-1 receptor.
Dual agonists acting at the GIP and GLP-1 receptors.
Triple agonists that add activity at the glucagon receptor. This is the category in which retatrutide is placed [9].
A review in Biomolecules devoted specifically to retatrutide frames the glucagon component as the feature that distinguishes it from earlier incretin-based compounds [9].
The three receptors and their natural hormones
Each target receptor normally responds to a hormone made by the gut or pancreas. Review articles on GLP-1-based medicines summarise their physiology as follows [6][10]:
Receptor | Natural hormone made by | Physiological roles described in reviews |
|---|---|---|
GLP-1 receptor | L-cells of the intestine | Glucose-dependent insulin release, suppression of glucagon, slower gastric emptying, appetite signalling in the brain |
GIP receptor | K-cells of the upper intestine | Glucose-dependent insulin release; receptors also present in fat tissue and the brain |
Glucagon receptor | Alpha cells of the pancreas | Raises glucose output from the liver; influences liver fat handling and energy expenditure |
The GLP-1 receptor
The GLP-1 receptor is the best-characterised of the three. A Diabetes Care review of GLP-1 medicines describes how activating it amplifies insulin secretion only when glucose is raised, dampens glucagon release and acts on appetite pathways [10]. These effects are the foundation on which dual and triple agonists were built.
The GIP receptor
GIP is the other major incretin hormone. Its role in combination molecules has been studied less, and reviews describe its contribution as an active area of research rather than a settled question [6][7].
The glucagon receptor: the unusual addition
Glucagon's classic job is to raise blood glucose, mainly by signalling the liver to release stored glucose. At first glance, that seems an odd target for a compound studied in obesity and type 2 diabetes. Reviews explain the rationale through glucagon's other actions. It acts on fat metabolism in the liver, and it is proposed to increase energy expenditure [7][9]. Pairing it with incretin activity is intended to keep those actions while the GLP-1 and GIP components offset the glucose-raising effect [9].
The design rationale: why combine all three
The reviews describe a layered logic [6][7][9]:
Intake side. GLP-1 receptor activity, possibly supported by GIP receptor activity, acts on appetite and gastric emptying.
Expenditure side. Glucagon receptor activity is proposed to raise energy expenditure, a lever that incretin-only compounds lack.
Glucose balance. The insulin-related effects of the incretin components are meant to counter glucagon's tendency to raise blood glucose.
Liver. The proposed hepatic actions of the glucagon component are consistent with liver fat being studied as a dedicated outcome, as in a randomized phase 2a trial in metabolic dysfunction-associated steatotic liver disease [11].
Two cautions apply. First, much of this rationale comes from physiology and preclinical research, and reviews present it as a hypothesis that human trials are testing [7][8]. Second, the effect of a multi-agonist depends on its receptor balance: how strongly it activates each receptor relative to the others. Reviews identify that balance as a central design question for the whole class [7][9]. Activity that is strong at one receptor and weaker at another can give a different profile from equal activity at all three.
What human trials measure, and what they cannot
Clinical trials do not measure receptor activation directly. They measure downstream outcomes that the mechanism predicts. Across the published and registered retatrutide research, these include:
Body weight in adults with obesity or overweight, in the phase 2 NEJM trial [4] and in the TRIUMPH-1 phase 3 study registered as NCT05929066 [1].
Glycaemic measures in adults with type 2 diabetes, in a phase 2 trial conducted in the USA [5]. They were also measured in two phase 3 trials: TRANSCEND-T2D-1, in people with inadequate glycaemic control on diet and exercise [12], and TRIUMPH-2, in adults with both obesity and type 2 diabetes [13][2].
Liver fat in a randomized phase 2a trial in metabolic dysfunction-associated steatotic liver disease (MASLD) [11].
These outcomes line up with the receptor rationale. Weight and appetite relate to the incretin components. Glycaemic measures relate to the balance between incretin and glucagon activity. Liver fat relates to the glucagon component. That fit is consistent with the proposed mechanism, but it is not proof of it.
Why the three receptors cannot be separated in trials
Because retatrutide is a single molecule, no trial arm can switch off one receptor and leave the others active. An outcome seen with retatrutide reflects the combined action of all three, plus the molecule's other properties. Comparisons with single or dual agonists can suggest what the glucagon component adds. Reviews note, however, that such comparisons are mostly indirect and made across trials with different populations and designs [7][8]. Attributing a specific result to a specific receptor therefore remains inference, not measurement.
Mechanism and tolerability
Mechanism also shapes the adverse-event profile. Gastrointestinal effects are well documented across GLP-1 receptor agonists [10], and the retatrutide-specific review discusses them in that class context [9]. Whether glucagon receptor activity contributes adverse-event patterns of its own is still an open research question. Safety reporting from the phase 3 programme is the main source of evidence on it, and our retatrutide guide summarises the side effects reported so far.
Open questions in the research
Based on the reviews and trial records above, several mechanistic questions remain unresolved:
Relative contribution. How much of the observed effect in humans comes from each receptor [6][7].
Long-term glucagon receptor activation. What sustained activity at this receptor means over years. The registered phase 3 programme, including TRIUMPH-1 [1], is the main source of longer-term human data.
Energy expenditure in humans. Whether the proposed rise in energy expenditure is measurable and meaningful in people, as opposed to preclinical models [8][9].
Durability after discontinuation. This question applies across the incretin class and is discussed in pipeline reviews [8].
Further reading
Mechanism questions are easier to follow with a grounding in receptor pharmacology and hormone physiology. A strong reference text explains how receptors are classified, what agonism, potency and selectivity mean, and how gut and pancreatic hormones regulate metabolism. When comparing titles, a few neutral criteria separate durable references from quickly dated ones:
Edition and date. Endocrinology and pharmacology move fast. Check the copyright year, and check whether recent chapters cover multi-receptor agonist design.
Level. Introductory texts suit general readers. Graduate-level pharmacology texts go deeper into receptor signalling and drug-receptor kinetics.
Referencing. Prefer books whose chapters cite primary literature, so claims can be traced and checked.
Authorship. Look for named academic authors or editors with stated institutional affiliations.
Format and price transparency. Compare print and ebook editions, and choose retailers that list the full price, including delivery, up front.
A textbook explains principles. It does not replace the primary papers, which carry the actual data. Reading a reference text alongside the sources listed at the end of this page gives the most reliable picture.
Frequently asked questions
Is retatrutide just another GLP-1 drug?
Not exactly. GLP-1 receptor activity is one of its three components, but it is designed to also activate the GIP and glucagon receptors [4][5]. Reviews classify it as a triple agonist, a step beyond single GLP-1 agonists and dual GIP/GLP-1 agonists [7][9].
Why include the glucagon receptor if glucagon raises blood glucose?
Reviews describe the glucagon component as a way to add actions on energy expenditure and liver fat metabolism [9]. The incretin components are intended to offset glucagon's glucose-raising effect [7][9]. Glycaemic outcomes were assessed in trials in people with type 2 diabetes, including TRANSCEND-T2D-1 and TRIUMPH-2 [12][13].
Can trial results show which receptor causes which effect?
No. A single molecule acts on all three receptors at once, so trials measure the combined outcome rather than isolating each receptor. Assigning effects to individual receptors relies on physiology, preclinical work and indirect comparisons with other compounds [7][8].
Last updated: 19 October 2026.
Related on this site
Is retatrutide FDA approved? Legal status and approval timeline
Retatrutide: mechanism, trial findings and side effects explained
How to read retatrutide trial results: endpoints, placebo, dropouts
Books about clinical trials: a reading list for following research
Retatrutide vs tirzepatide: how the trial designs and data compare
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.